(LEAD) Regulator concludes 'intentional' accounting breach by Samsung BioLogics
(ATTN: UPDATES with regulator's ruling in first 2 paras; CHANGES headline)
SEOUL, July 12 (Yonhap) -- The financial regulator said Thursday it has concluded that a 2015 accounting breach by Samsung BioLogics Co. was intentional and the biopharmaceutical company clearly violated accounting rules.
The ruling by the Financial Services Commission (FSC) is expected to deal a serious blow to Samsung BioLogics, which has strongly denied allegations of accounting breach.
In May, financial authorities gave a preliminary notice to Samsung BioLogics that it broke accounting rules in 2015.
The regulatory probe centers on questions about the biopharmaceutical company's sudden profits in 2015 after years of losses. Samsung BioLogics reported a net profit of 1.9 trillion won (US$1.72 billion) that year after changing the method used to calculate the value of its affiliate, Samsung Bioepis.
Samsung BioLogics has claimed that the change was in line with international accounting standards.
(END)
-
1 
31 diabetes drugs banned for suspected carcinogen substance
-
2 
(LEAD) KBO bans ex-major leaguer Kang Jung-ho for 1 year before potential return
-
3 
(LEAD) Itaewon cluster grows to 237, six stages of transmission confirmed
-
4 
'No mask, no ride' policy goes smoothly on buses, taxis
-
5 
(2nd LD) S. Korea moves to limit classroom crowding amid persistent outbreak in capital area
-
1 
Ex-CEO of cosmetics firm Skinfood gets 5-yr jail term for stealing revenue
-
2 
(4th LD) S. Korea struggling to contain cluster-traced virus spread in greater Seoul area
-
3 
(LEAD) S. Korea braces for more infections in greater Seoul area
-
4 
S. Korea to enhance quarantine measures in greater Seoul area amid spiking cases
-
5
(2nd LD) S. Korea moves to limit classroom crowding amid persistent outbreak in capital area
